Gail Eckhardt
- Oncology top 5%
- Cancer Treatment and Pharmacology 2
- Pancreatic and Hepatic Oncology Research 2
- Biotechnology top 5%
- Cancer Research and Treatments 3
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 2
- Cancer Genomics and Diagnostics 2
- Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 3
- RNA modifications and cancer 2
- Cell death mechanisms and regulation 2
- Genetics top 10%
- Co-authors
- Razelle KurzrockMichael S. GordonDavid H. KirnCarla HeiseG I RodriguezIan GanlyStuart KayeSabine Eckhardt
- Cited by
- OncologyBiotechnologyCancer Research
- Journals
- Journal of Clinical Oncology (5 papers)Annals of Oncology (3 papers)Cancer Research (3 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Gail Eckhardt
19 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 900
- Biotechnology 170
- Cancer Research 273
- Molecular Biology 850
- Genetics 319
Countries citing papers authored by Gail Eckhardt
This map shows the geographic impact of Gail Eckhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail Eckhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail Eckhardt more than expected).
Fields of papers citing papers by Gail Eckhardt
This network shows the impact of papers produced by Gail Eckhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail Eckhardt. The network helps show where Gail Eckhardt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gail Eckhardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 101 | |
| 2 | 2018 | 1 | |
| 3 | 2017 | 5 | |
| 4 | 2017 | 1 | |
| 5 | 2017 | 168 | |
| 6 | 2016 | 33 | |
| 7 | 2014 | 49 | |
| 8 | 2013 | 2 | |
| 9 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialbreakdown → | 2012 | 424 |
| 10 | 2009 | 1 | |
| 11 | 2009 | 172 | |
| 12 | 2007 | 18 | |
| 13 | 2006 | 77 | |
| 14 | 2006 | 46 | |
| 15 | 2006 | 9 | |
| 16 | 2000 | 25 | |
| 17 | A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. | 2000 | 348 |
| 18 | 1998 | 122 | |
| 19 | 1997 | 0 | |
| 20 | [HDL and LDL cholesterol changes in psychological stress in relation to stress experience]. | 1984 | 3 |
About Gail Eckhardt
Gail Eckhardt is a scholar working on Biotechnology, Cancer Research and Oncology, having authored 20 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Research and Treatments (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Cancer Treatment and Pharmacology (2 papers), RNA modifications and cancer (2 papers), Cell death mechanisms and regulation (2 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (900 citations), Biotechnology (170 citations) and Cancer Research (273 citations). Gail Eckhardt has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Razelle Kurzrock, Michael S. Gordon, David H. Kirn, Carla Heise, G I Rodriguez, Ian Ganly, Stuart Kaye, Sabine Eckhardt, A.G. Robertson and Daniel D. Von Hoff. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Molecular Carcinogenesis and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.